Hypercholesterolemia News and Research

RSS
Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood. Cholesterol is a waxy, fat-like substance that is produced in the body and obtained from foods that come from animals (particularly egg yolks, meat, poultry, fish, and dairy products). The body needs this substance to build cell membranes, make certain hormones, and produce compounds that aid in fat digestion. Too much cholesterol, however, increases a person's risk of developing heart disease.

People with hypercholesterolemia have a high risk of developing a form of heart disease called coronary artery disease. This condition occurs when excess cholesterol in the bloodstream is deposited in the walls of blood vessels, particularly in the arteries that supply blood to the heart (coronary arteries). The abnormal buildup of cholesterol forms clumps (plaque) that narrow and harden artery walls. As the clumps get bigger, they can clog the arteries and restrict the flow of blood to the heart. The buildup of plaque in coronary arteries causes a form of chest pain called angina and greatly increases a person's risk of having a heart attack.

Inherited forms of hypercholesterolemia can also cause health problems related to the buildup of excess cholesterol in other tissues. If cholesterol accumulates in tendons, it causes characteristic growths called tendon xanthomas. These growths most often affect the Achilles tendons and tendons in the hands and fingers. Yellowish cholesterol deposits under the skin of the eyelids are known as xanthelasmata. Cholesterol can also accumulate at the edges of the clear, front surface of the eye (the cornea), leading to a gray-colored ring called an arcus cornealis.
Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Cerenis’ SAMBA and MODE Phase II Studies Meet Primary Endpoints for Treatment of FPHA, HoFH

Cerenis’ SAMBA and MODE Phase II Studies Meet Primary Endpoints for Treatment of FPHA, HoFH

Genzyme, Isis receive 2014 Partners in Progress Corporate Award for KYNAMRO injection

Genzyme, Isis receive 2014 Partners in Progress Corporate Award for KYNAMRO injection

Controlling low-density lipoprotein-cholesterol levels: an interview with Jay Edelberg, M.D., Sanofi and Bill Sasiela, Ph.D., Regeneron

Controlling low-density lipoprotein-cholesterol levels: an interview with Jay Edelberg, M.D., Sanofi and Bill Sasiela, Ph.D., Regeneron

Synageva announces publication of LAL Deficiency review in Atherosclerosis

Synageva announces publication of LAL Deficiency review in Atherosclerosis

Clinical Research Forum announces winners of third annual Top 10 Clinical Research Achievement Awards

Clinical Research Forum announces winners of third annual Top 10 Clinical Research Achievement Awards

Two Penn researchers selected as recipients of prestigious Clinical Research Achievement Award

Two Penn researchers selected as recipients of prestigious Clinical Research Achievement Award

Amgen reports positive findings from AMG 145 Phase 3 studies in patients at risk for cardiovascular disease

Amgen reports positive findings from AMG 145 Phase 3 studies in patients at risk for cardiovascular disease

Findings underscore importance of universal pediatric cholesterol screening

Findings underscore importance of universal pediatric cholesterol screening

Amgen announces results from Phase 3 TESLA Trial of evolocumab in patients with HoFH

Amgen announces results from Phase 3 TESLA Trial of evolocumab in patients with HoFH

Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

Amgen reports that Phase 3 DESCARTES study for high cholesterol meets primary endpoint

Amgen reports that Phase 3 DESCARTES study for high cholesterol meets primary endpoint

Sanofi and Regeneron Pharmaceuticals team up with ACC to enhance clinical research with alirocumab

Sanofi and Regeneron Pharmaceuticals team up with ACC to enhance clinical research with alirocumab

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

Alnylam initiates Phase II study with ALN-TTRsc for treatment of ATTR

Alnylam initiates Phase II study with ALN-TTRsc for treatment of ATTR

Alnylam presents new pre-clinical data with ALN-AT3 for treatment of hemophilia and RBD

Alnylam presents new pre-clinical data with ALN-AT3 for treatment of hemophilia and RBD

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Hypertension skyrocketing in India

Hypertension skyrocketing in India

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.